APA (7th ed.) Citation

Y, B., L, E., NA, A., NA, A., WA, A., & AM, M. (2026). Integrated in silico investigation of an androstendiol derivative (monoxetanol) as a potential anti-prostate cancer agent: Insights from molecular docking, MD simulations, MM/PBSA, ADMET, and DFT analyses. In silico pharmacology, 14(2), 134. https://doi.org/10.1007/s40203-026-00626-3

Chicago Style (17th ed.) Citation

Y, Bekkar, Elhafnaoui L, Al-Masoudi NA, Abdul-Rida NA, Al-Masoudi WA, and Mahdi AM. "Integrated in Silico Investigation of an Androstendiol Derivative (monoxetanol) as a Potential Anti-prostate Cancer Agent: Insights from Molecular Docking, MD Simulations, MM/PBSA, ADMET, and DFT Analyses." In Silico Pharmacology 14, no. 2 (2026): 134. https://doi.org/10.1007/s40203-026-00626-3.

MLA (9th ed.) Citation

Y, Bekkar, et al. "Integrated in Silico Investigation of an Androstendiol Derivative (monoxetanol) as a Potential Anti-prostate Cancer Agent: Insights from Molecular Docking, MD Simulations, MM/PBSA, ADMET, and DFT Analyses." In Silico Pharmacology, vol. 14, no. 2, 2026, p. 134, https://doi.org/10.1007/s40203-026-00626-3.